All persons and entities who purchased or otherwise acquired the publicly traded securities of McKesson Corp. between October 24, 2013 and October 27, 2016.

McKesson Corp. common stock.

The complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) McKesson and several of its industry peers colluded to fix the price of certain generic drugs; (ii) the collusive conduct constituted a violation of federal antitrust laws; (iii) consequently, McKesson’s revenues during the Class Period were, in part, the result of illegal conduct and were therefore unsustainable; (iv) McKesson lacked effective internal controls over financial reporting; and (v) as a result, McKesson’s public statements were materially false and misleading at all relevant times.

Class action on behalf of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of McKesson Corp. between October 24, 2013 and October 27, 2016, pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.